Daiichi Sankyo Company, Limited announced that its subsidiary in China, Daiichi Pharmaceutical (Beijing) Co, Ltd filed an application for KMD-3213 (silodosin) to China's State Food and Drug Administration. The drug was developed for treatment of dysuria associated with benign prostatic hyperplasia.
The details can be read here.
No comments:
Post a Comment